Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

An atherosclerosis, inhibitor technology, applied in the field of treatment and/or prevention of atherosclerotic injury

Inactive Publication Date: 2001-08-29
WARNER-LAMBERT CO
View PDF53 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, matrix metalloproteinase inhibito

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] Coadministration of a bioeffective ACAT inhibitor with a matrix metalloproteinase (MMP) inhibitor attenuates atherosclerotic damage and promotes the development of stable plaque morphology. ACAT inhibitors have been shown to reduce monocyte-macrophage accumulation in atherosclerotic lesions in rabbits. Additionally, monocyte-macrophages have been reported to secrete such matrix metalloproteinases as MMP-7 and -9, while smooth muscle cells have been noted to secrete MMP-1, -2, and -3. Inhibition of ACAT that directly reduces the accumulation of lipid-filled monocyte-macrophages will reduce MMP sources. Inhibition of MMPs will also limit the development of atherosclerotic lesions by limiting the remodeling of the extracellular matrix to reduce the migration of smooth muscle cells and monocytes to the developing intima. Co-administration of the two agents will limit the formation of new lesions by inhibiting cellular accumulation and by preventing both matrix remodeling a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.

Description

Background of the invention [0001] Enzymes known as native matrix metalloproteinases (MMPs) are a class of naturally occurring enzymes found in most mammals. They are zinc proteases that hydrolyze collagen, proteoglycans, and glycoproteins. These types include gelatinase A and B, stromelysin-1 and -2, fibroblastic collagenase, neutrophil collagenase, stromelysin, metalloelastase, and interstitial collagenase. These enzymes have been linked to many diseases caused by damage to connective tissue, such as rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis, and even tumor metastasis. MMP expression in atherosclerosis in White A., Bocan T.M.A., Boxer P.A., Peterson J.T., Schrier D. Presentation of second-generation matrix metalloproteinase inhibitors for treatment, Curr.Phar.Design 3:45-58 (1997). To date, matrix metalloproteinase inhibitors have not been used with ACAT inhibitors. [0002] MMP inhibitors and their preparation are taught in US Patent Applica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61KC07D243/10A61K31/00A61K31/17A61K31/18A61K31/195A61K31/197A61K31/198A61K31/216A61K31/255A61K31/335A61K31/343A61K31/351A61K31/352A61K31/353A61K31/357A61K31/381A61K31/385A61K31/397A61K31/403A61K31/404A61K31/4164A61K31/4178A61K31/4184A61K31/426A61K31/427A61K31/4365A61K31/438A61K31/44A61K31/4427A61K31/443A61K31/47A61K31/472A61K31/54A61K31/541A61K31/55A61K45/00A61K45/06A61P9/10A61P43/00C07D205/08C07D209/18C07D213/75C07D213/76C07D215/38C07D217/04C07D233/60C07D233/70C07D233/84C07D233/88C07D235/14C07D239/48C07D277/20C07D277/30C07D279/10C07D307/81C07D307/91C07D307/94C07D309/10C07D311/20C07D311/22C07D311/58C07D313/08C07D313/12C07D319/06C07D319/18C07D333/22C07D339/08C07D401/12C07D403/12C07D405/04C07D405/12C07D491/113C07D495/04
CPCA61K45/06A61P43/00A61P9/10A61K31/495
Inventor T·M·A·博肯
Owner WARNER-LAMBERT CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap